Tomas Kiselak's Net Worth
$45.6 Million
Who is Tomas Kiselak?
Tomas Kiselak has an estimated net worth of $45.6 Million. This is based on reported shares across multiple companies, which include Apogee Therapeutics, Inc., Viridian Therapeutics, Inc.\DE, Spyre Therapeutics, Inc., and Dianthus Therapeutics, Inc. /DE/.
SEC CIK
Tomas Kiselak's CIK is 0001830177
Past Insider Trading and Trends
2023 was Tomas Kiselak's most active year for acquiring shares with 9 total transactions. Tomas Kiselak's most active month to acquire stocks was the month of August. 2023 was Tomas Kiselak's most active year for disposing of shares, totalling 1 transactions. Tomas Kiselak's most active month to dispose stocks was the month of December. 2023 saw Tomas Kiselak paying a total of $11,398,631.97 for 3,587,571 shares, this is the most they've acquired in one year. In 2024 Tomas Kiselak cashed out on 892,529 shares for a total of $0.00, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Apogee Therapeutics, Inc. (APGE) Snapshot price: $36.665
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
| 2.05M |
Mar 28
| |||
Form 4
| -88.53% | -790.20K |
—
|
—
| 102.33K |
Scheduled
|
Jan 29
| ||
Form 4
|
∞
| 2.94M |
$17.00 | $49,999,992.00 | 2.94M |
Jul 13
| |||
| No matching records found | |||||||||
Spyre Therapeutics, Inc. (AGLE) No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +961.81% | 3.64M |
—
|
—
| 4.02M |
Apr 25
| |||
Form 4
| -76.36% | -2.62M |
—
|
—
| 812.08K |
Dec 29
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Dec 7
| |||
Form 4
|
∞
| 3.44M |
—
|
—
| 3.44M |
Nov 24
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Dianthus Therapeutics, Inc. /DE/ (DNTH) Snapshot price: $22.45
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
| 2.7M |
Apr 1
| |||
Form 4
| +43.26% | 834.33K |
$12.00 | $10,012,008.00 | 2.76M |
Jan 22
| |||
Form 4
| +1.30% | 24.67K |
$13.63 | $336,252.10 | 1.93M |
Sep 29
| |||
Form 4
| +1.60% | 30K |
$13.15 | $394,500.00 | 1.9M |
Sep 26
| |||
Form 4
| +1.63% | 30K |
$13.20 | $396,000.00 | 1.87M |
Sep 19
| |||
Form 4
| +1.33% | 24.25K |
$11.20 | $271,679.87 | 1.84M |
Sep 11 - Sep 13
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Viridian Therapeutics, Inc.\DE (VRDN) Snapshot price: $17.74
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 14
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 8
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 3
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 4
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Oct 27
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||